Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease

The design of novel inhibitors to target BACE1 with reduced cytotoxicity effects is a promising approach to treat Alzheimer's disease (AD). Multiple clinical drugs and antibodies such as AZD3293 and Solanezumab are being tested to investigate their therapeutical potential against AD. The curren...

Full description

Bibliographic Details
Main Authors:	Mubashir Hassan, Saba Shahzadi, Sung Y. Seo, Hany Alashwal, Nazar Zaki, Ahmed A. Moustafa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-06-01
Series:	Frontiers in Computational Neuroscience
Subjects:	Alzheimer's disease computational modeling dynamic simulation AZD3293 solanezumab
Online Access:	https://www.frontiersin.org/article/10.3389/fncom.2018.00034/full

Similar Items

The Use of Monoclonal Antibodies in the Treatment of Alzheimer Disease
by: Hemen Moradi-Sardareh, et al.
Published: (2016-09-01)

Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways
by: Rosalinda Mejía-Rodríguez, et al.
Published: (2023-03-01)

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia
by: Diana Otero Svaldi, et al.
Published: (2022-01-01)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
by: Maryam Talebpoor, et al.
Published: (2022-06-01)

A case report of toxic epidermal necrolysis associated with AZD-9291
by: Wang J, et al.
Published: (2018-07-01)

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling
by: Yi Zhao, et al.
Published: (2017-04-01)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
by: Jian Zhu, et al.
Published: (2019-07-01)

Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
by: Weimin Hu, et al.
Published: (2023-03-01)

Evaluation of AZD1446 as a Therapeutic in DYT1 Dystonia
by: Chelsea N. Zimmerman, et al.
Published: (2017-06-01)

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo
by: Byung-Hyun Cha, et al.
Published: (2021-10-01)

Comprehensive analysis of circular RNA profiling in AZD9291‐resistant non‐small cell lung cancer cell lines
by: Tianxiang Chen, et al.
Published: (2019-04-01)

In Vivo Anticancer Activity of AZD3965: A Systematic Review
by: Ana Silva, et al.
Published: (2021-12-01)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
by: S. Lindsey Davis, et al.
Published: (2022-10-01)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
by: Chandima Jeewandara, et al.
Published: (2022-04-01)

Propofol and AZD3043 Inhibit Adult Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes
by: Malin Jonsson Fagerlund, et al.
Published: (2016-02-01)

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
by: Sylwia Ammoun, et al.
Published: (2010-01-01)

Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer
by: Ana Silva, et al.
Published: (2023-11-01)

Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer
by: Chen S, et al.
Published: (2016-03-01)

Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma
by: Nilsson M, et al.
Published: (2022-08-01)

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
by: Xuejiao Liu, et al.
Published: (2019-05-01)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
by: Prothon S, et al.
Published: (2022-02-01)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
by: Jingcao Zheng, et al.
Published: (2023-01-01)

AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways
by: Wei Yin, et al.
Published: (2021-01-01)

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas
by: Dietmar Krex, et al.
Published: (2023-03-01)

Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model
by: Li Liu, et al.
Published: (2014-03-01)

Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case–control study
by: Debdutta Bhattacharya, et al.
Published: (2023-01-01)

Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development
by: Tae Hyun Park, et al.
Published: (2020-10-01)

The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
by: Yu Ran Na, et al.
Published: (2021-10-01)

Antibody Response and Adverse Events of AZD1222 COVID-19 Vaccination in Patients Undergoing Dialysis: A Prospective Cohort Study
by: Hsi-Hao Wang, et al.
Published: (2022-09-01)

Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system
by: Mostafa Enayatrad, et al.
Published: (2023-03-01)

AZD9291 Resistance Reversal Activity of a pH‐Sensitive Nanocarrier Dual‐Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC
by: Yu Gu, et al.
Published: (2021-01-01)

Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers
by: Hamed Zare, et al.
Published: (2022-10-01)

Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
by: Rourou Xiao, et al.
Published: (2022-07-01)

Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
by: Marta Braga, et al.
Published: (2020-06-01)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
by: Piyarat Limpawittayakul, et al.
Published: (2022-11-01)

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)
by: Gustavo H. Kijak, et al.
Published: (2023-11-01)

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma
by: Bateman ED, et al.
Published: (2018-05-01)

AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells
by: Chen X, et al.
Published: (2020-02-01)

In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3
by: Hwang G, et al.
Published: (2017-07-01)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
by: Prothon S, et al.
Published: (2019-11-01)